|
|
 |
|
Viewing report
|
|
|
|
Market Dynamics: Arthritis - The Ongoing Battle for Supremacy
Datamonitor, May 2002
This in-depth look at the lucrative, high-growth arthritis market examines the key products, events, and data that are driving sales around the globe. With comprehensive coverage of the major pharmaceutical markets, this analysis deciphers the current and future commercial attractiveness of the market by translating drivers and sales data into insightful recommendations.Key data and detailed analysis of the 7 leading country markets: the US, Japan, Germany, France, Italy, Spain, and the UKIn-depth analysis and forecasts for the overall arthritis market as well as breakdowns for the Dmard, Nsaid, and HA viscosupplement classesDetailed company analysis featuring strengths, weaknesses, forecasted sales, and pipelinesNsaid and Dmard growth rates are being driven by Cox-2s and biologics respectively, showing that not all competitors are enjoying overall market growth. With high growth rates, increasing physician acceptance, higher prices that drive additional market value growth, and a number of promising pipeline products, these drug classes have rapidly become the most important in the treatment of arthritis.A shift in the RA treatment paradigm towards more aggressive, early therapy has contributed heavily to strong sales for Dmards, particularly biologics. As a result, Dmards now represent over 12% of the global arthritis market.The fierce competition between Pfizer and Merck for control of the arthritis leadership continues to grow with the success of Cox-2 inhibitors. Reports of adverse events and the launch of 2nd-generation products is not only impacting the current market, but will shape the future of competition within the arthritis market.Understand your competitor’s strengths and weaknesses, while identifying potential licensing, co-promotion, and partnership opportunities.Assess the potential of key drug classes and the overall arthritis drug market, as well as the factors key to each product’s success.Attain knowledge beyond current market conditions, with an understanding of the launches and events that will both help and hinder each product.Using detailed forecasts, plan your future strategy with confidence
Customers who bought this item also bought
Drugs of Tomorrow 2002: Arthritis
Drugs of Tomorrow 2000: Arthritis - Developments For a Competitive Market
Treatment Algorithms: Rheumatoid Arthritis 2nd Edition - Dmards Move to Front of Pack
Commercial Insight: Osteoarthritis and Rheumatoid Arthritis - New Growth In A Mature Market
Br Malls Participacoes Sa
Br. Holdings Corporation
Arthritis in the United States
Pipeline Insight: Disease Modification in Rheumatoid Arthritis - New drug targets compete in crowded market
The Rheumatoid Arthritis Market - Competitive Landscape and Clinical Stage Analysis
Pipeline Insight: Rheumatoid Arthritis and Osteoarthritis - Striving for innovation among me-toos
Rheumatoid Arthritis Drug Discoveries: What The Future Holds
Arthritis in the United States 2009
|
|
|
|
